CanSino Biologics (HKG:6185, SHA:688185) expects to book a net loss attributable to the shareholders between 335 million yuan and 385 million yuan for 2024, narrower than 1.48 billion yuan logged for the preceding year, a Friday Hong Kong bourse filing said.
The biopharmaceutical company attributed the reduction in expected loss to an increase in the group's revenue resulting from the exclusive competitive market position of one of its vaccines, Menhycia, increased operational efficiency, and cost-saving measures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.